In silico QSAR studies of anilinoquinolines as EGFR inhibitors.
Members of the epidermal growth factor receptor (EGFR) family of proteins are frequently overactive in solid tumors. A relatively new therapeutic approach to inhibit the kinase activity is the use of ATP-competitive small molecules. In silico techniques were employed to identify the key interactions between inhibitors and their protein receptors. A series of EGFR inhibitory anilinoquinolines was studied within the framework of hologram quantitative structure activity relationship (HQSAR), density functional theory (DFT)-based QSAR, and three-dimensional (3D) QSAR (CoMFA/CoMSIA). The HQSAR analysis implied that substitutions at certain sites on the inhibitors play an important role in EGFR inhibition. DFT-based QSAR results suggested that steric and electronic interactions contributed significantly to the activity. Ligand-based 3D-QSAR and receptor-guided 3D-QSAR analyses such as CoMFA and CoMSIA techniques were carried out, and the results corroborated the previous two approaches. The 3D QSAR models indicated that steric and hydrophobic interactions are dominant, and that substitution patterns are an important factor in determining activity. Molecular docking was helpful in identifying a bioactive conformer as well as a plausible binding mode. The docked geometry-based CoMFA model with steric and electrostatic fields effect gave q(2) = 0.66, r(2) = 0.94 with r(2) (predictive) = 0.72. Similarly, CoMSIA with hydrophobic field gave q(2) = 0.59, r(2) = 0.85 with r(2) (predictive) = 0.63. Bulky groups around site 3 of ring "C", and hydrophilic and bulky groups at position 6 of ring "A" are desirable, with a hydrophobic and electron-donating group at site 7 of ring "A" being helpful. Accordingly, potential EGFR inhibitors may be designed by modification of known inhibitors.
Pasha
Farhan Ahmad
FA
Computational Science Center, Korea Institute of Science and Technology, Seoul, Korea.
Muddassar
Muhammad
M
Srivastava
Anil Kumar
AK
Cho
Seung Joo
SJ
D000814:Aniline Compounds / Q000737:chemistry / Q000494:pharmacology; D003198:Computer Simulation; D004791:Enzyme Inhibitors / Q000737:chemistry; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008958:Models, Molecular; D011485:Protein Binding; D021281:Quantitative Structure-Activity Relationship; D011804:Quinolines / Q000737:chemistry* / Q000494:pharmacology; D055672:Static Electricity
D000814:Aniline Compounds; D004791:Enzyme Inhibitors; D011804:Quinolines; D066246:ErbB Receptors